• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel pentapeptides and their C-terminal esters and amides are prepared. The compounds of the formula I are obtained by condensation in accordance with processes which are customary in peptide chemistry. The symbols in formula I have the meaning given in Claim 1. The compounds of the formula I and their salts have an analgesic activity which is comparable with that of morphine. <IMAGE>
    公开号:SU772481A3
    申请号:SU772521797
    申请日:1977-09-15
    公开日:1980-10-15
    发明作者:Байюс Шандор；Ронай Андраш；Секели Иожеф；Граф Ласло；Мохай Жужа
    申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    This invention relates to a process for the preparation of new pentapeptides or their salts with biological activity, which can be used in medicine.
    In peptide chemistry, it is widely known. The method for producing peptides by gradually increasing the peptide chain by condensing amino acids or peptide fragments using various methods, for example, carbodiimide, activated ester method, and p. Ll.
    The purpose of the invention is to obtain, using known methods, peptide chemistry of new pentapeptides or their salts, which have interesting pharmacological properties.
    The goal is achieved by the described method of producing pentapeptides of formula I
    Tyr-A-G1y-Phe-B-X-Y /
    where A is D-Ala, 0-Met, D-NLeu,
    B - N-Leu, izoi, Pro,
    X - Oh, NH,
    Y - H, Me, Et,
    or their esters or their amides, or their salts, which consists in
    norleucine, isoleucine or proline, or their ester or amide derivatives are condensed with the following amino acid and / or peptide fragments having N-terminus of protecting groups and then removing the protective groups and isolating the desired product as an ether, amide, salt or acid.
    fO
    As a preferred variant of the process, the condensation is carried out either by the carbamide method or by using the activated
    15 . esters.
    The following abbreviations are used in the text.
    The three letter abbreviations of amino acids are as follows:
    20
    Ala - alanine
    G1 y - glycine
    31e - isoleucine
    Leu - Leucine
    Met - Methionine
    25
    .he - phenylalanil
    Pro - Proline
    Tyr - Tyrosine
    Nle - norleucine-2-aminohexanoic acid.
    30 Abbreviation in itself means an amino acid in the L-configuration (with the exception of the inactive one), while in the case of the D-amino acid, e will be marked each time, for example, D-Met is O-methionine. Z - benzyloxycarbonyl-carbobenzoxy, Baugh - tert-butyloxycarbonyl, OTSP - pentachlorophenoxy, ONP - 4-nitrophenoxy, Et - ethyl. Met - methyl. The Kg values were determined by thin layer chromatography on silica gel in the following solvent systems: Chloroform, methanol Ethyl acetate-pyridine-acetic acid240: 30: 6: 11 lot-water Ethyl acetate-pyridine-acetic acid12: 20: 6: 11 lot-water Ethyl acetate- pyridine-uksu.sna acid 60: 20: 7: 11 lot-water Ethyl acetate-pyri. dine-acetic acid 30: 20: 6: 11 lot-water The solutions are evaporated under reduced pressure in a water bath at 40 ° C. Amino acid analyzes of the peptides were carried out using an analyzer of the type T1C-5AN, after complete hydrol / isa (6N HCl, 24 h). Example 1. Preparation of L-tyrosyl-0-alanine-glycyl-1-phenylalanyl-L-norleucine. A. Methyl ester of benzyloxycarb nyl-2-phenylalanine-p-1, -norleycine. 1 isomeric acid / g (10 M1Fields) Z-Phe OTCP and 2 g (11 tlolei H – N 1 e-OMe HC 1 in 10 ml of pyridine was added 1.2 (11 mmol) N-methylmorphol and the mixture was left for 3 The reaction mixture is evaporated, the residue is dissolved in 50 ml of ethyl acetate and water (1: the organic phase is separated and washed with 1N hydrochloric acid and water, dried over sodium sulfate and evaporated. The residue is washed with ether, filtered, washed with ether and dried, yield 3.6 g (85%), mp 123-124 RP 0.89-0.93 B. Methyl benzyloxycarbonyl glycyl-1-phenyl-aryl-1-noryl methyl ester 5.55 g (13 mmol) Z-Phe-Nle-OMe (Example IA) is dissolved in 100 ml of methanol and g At the end of the reaction (k | 0.23-0.25), the catalyst is filtered off, the solution is evaporated and the residue is dissolved in 25 ml of pyridine. After adding 4.66 g (12 mmol) of Z-Cly The -OTCP mixture is left to stand for 3 hours. The reaction mixture is evaporated. The residue is dissolved in ether, filtered, taken up in ether and dried. Yield 5.28 g (91%), mp 110112 ° C, R 0.30-0.90 B. Benzyloxycarbonyl-1-tyrosyl-D-alanyl-glycine-L-phenylalanyl-1-iorleucine methyl ester. 1.92 g (4 mmol) Z-C.ly-Phe Nle-OMe. (Example 1B) is dissolved in 30 ml of methanol and hydrogenated in the presence of a palladium catalyst. At the end of the reaction (R 0.10-0.20), the catalyst is filtered off, the solution is evaporated and the residue is dissolved in 8 ml of pyridine. After the addition of 1.6 g (4 mmol) of Z-D-Ala-OTCP, the mixture is left to stand for 3 hours. The reaction mixture is evaporated, the residue is dissolved in ether, filtered, washed with ether and dried. The resulting product (, 67-0.70) is dissolved in 50 ml of a methanol-water-dimethylformamide mixture (1: 1: 1) and hydrogenated in the presence of a palladium catalyst. At the end of the reaction (Rr 0.24-0.29) the catalyst is filtered, the solution is evaporated and the residue is dissolved in ml of pyridine. After adding 1.75 g (3.5 mmol) of Z-Tyr-OTCP, the mixture is left for 5 hours, evaporated, the residue is dissolved in 30 ml of ethyl acetate, washed with water, dried over sodium sulfate and evaporated. The residue is dissolved in a mixture of ether and H-heptane (1: 1), filtered, washed with water, a mixture (1: 1) and cyDjaT. Yield 2.0 g 180%), so pl. 195 ° C (wrinkles at 190 ° C), R 0.73 O 78. G. L-Tyroel-O-alanyl-glycine-L-phenyl-alanyl-1-norleucine. 1.15 g of X1.6 mmol) Z-Tyr-D-Ala-Gly-Phe-Nle-OMe (Example 1c) was suspended in a mixture of 4 ml of methanol and 2 ml of acetone, washed with 0.5N. sodium hydroxide in the presence of thymolphthalein as an indicator. When the alkali absorption slowed down, the mixture was diluted with 10 ml of water and extracted with ethyl acetate (3 x 5 ml). The ethyl acetate layer was separated, evaporated to give 0.3 g (26%) of the protected pentapeptide ester. The aqueous phase is acidified. 0.5 n. sulfuric acid, the product precipitated (Rj. 0.250, 35), is suspended in 50 ml of 80% acetic acid and hydrogenated in the presence of a palladium catalyst. In the course of the reaction, the product dissolves. The catalyst is filtered off, the solution is evaporated and the residue is dissolved in 4 ml of cold water. The resulting crystalline substance is filtered, washed with cold water and dried. Yield 0.47 g (70%), R | 0,19-0,23. Amino acid analysis: Gly 1.0; Ala 1., 02; Nle 1.02; 0.98, Phe 1 (for comparison). Example 2. Preparation of 1-tyrosyl-0-alanyl-glycyl-1-phenylalanyl-1-norleucine methyl ester hydrochloride. 0.36 g (0.5 mmol) of D-Tu r-D-Al a-G 1 y-PJie-OMe (example ID) are suspended in 30 ml of acetic acid and hydrogenated in the presence of a palladium catalyst. At the end of the reaction, the catalyst is filtered off, the solution is evaporated and the residue is dissolved in 1 ml of 1N. methanol and hydrochloric acid and then diluted with eFioom. The precipitated product is filtered, washed with ether and dried and dried. Yield 0.3 g (93%) of the final pentapeptide ester hydrochloride; R | 0.55-0.60. Example 3. Obtaining L-tyro 3-O-methioNYL-glycine-L-phenylalanyl-L-norleucine. 1.8 g of 0.7 / ml (8) Z-G1y-Phe-N1e-OMe (Example 1B) is dissolved in 30 ml of methanol and hydrogenated in the presence of a palladium catalyst. At the end of the reaction (Rr. 0.100, 20), the catalyst is filtered and the solution is evaporated. The residue is dissolved in 4 ml of pyridine. Then, 1.56 g (3.65 Nmole) of Bore-D-Met-OBSR is added and the solution is left for 5 hours. The reaction mixture is evaporated, the residue is triturated with a mixture of ether and n-heptane (1: 1), filtered, washed with the mixture and dried. The product thus obtained (R 0.70-0.75) is left to stand for 30 minutes with 5 liters 2 n. hydrochloric acid in ethyl acetate, then diluted with kzt I-heptane, the residue is filtered off, washed with n-heptane, dried in vacuum in the presence of potassium hydroxide. The product obtained (1.5 g; 17-0.27) is suspended in a mixture of 2 ml of pyridine and 2 ml of dimethyl formamide. After the addition of 1.6 g (3 mmol) of Boc-Tug-OTCR and 0.7 g (6 dm) of N-methylmorpholine, the mixture is agitated until the addition of the Lens are dissolved, and then left to stand for nights The reaction mixture was concentrated in vacuo and diluted with 30 ml of ethyl acetate and 30 ml of 0.5N. sulfuric acid. The organic phase is separated, washed with 0.5N. sulfuric acid and water, dried over sodium sulfate and evaporated. The residue is dissolved in 5 ml of acetone and washed with 1N. sodium hydroxide in the presence of thymolphthalein as an indicator. At the end of the reaction, the solution is acidified with 0.5N. sulfuric acid and shaken with ethyl acetate. The ethyl acetate phase is evaporated and then 10 ml of 2N is added to the residue. hydrochloric acid in ethyl acetate and the mixture is stirred. After 30 minutes, the suspension obtained is diluted with 10 ml of water and the aqueous phase is neutralized with M-methylmorpholine. During cooling of the precipitate, the crystals are filtered off, washed with cold water and dried. The output of 1.13 g (60%) of Pentapeptide, Rf 0.3-0.4. Amino acid analysis: Gly 1,0; Met 0.98; Nle 1 .0; 0.96; Phe 1 for comparison). Example 4.-Preparation of L-tyrosyl-0-alanyl-glycyl-1-phenylalanyl-1-izoleptsina. A. Glycyl-1-phenylalanil-1-isoleucine. 1.95 g (7 mmol) of H-Phe-31e-OH is suspended in 10 ml of pyridine, then 0.98 g (7 mg mol) of triethylamine and 2.72 g (7 mmol) of Z-Gly-OTCP are added. The mixture is stirred until complete dissolution, the added substances are left to stand overnight. The reaction mixture is evaporated, the residue is dissolved in 50 ml of ethyl acetate and 0.5N is added. sulfuric acid to a pH of the aqueous phase 2-3. The organic phase is separated, washed with water, then the N-benzyloxycarbonyl peptide is extracted with a 5% sodium hydrogen carbonate solution (3 x 20), the combined extracts are acidified with 0.5N. sulfuric acid, the precipitated peptide is extracted with ethyl acetate and the ethyl acetate solution is evaporated. The residue (R 0.5-0.6) is dissolved in 60 ml of methanol and hydrogenated in the presence of a palladium catalyst. The catalyst is filtered off, washed with acetic acid, the filtrate is combined with the washing liquid and evaporated. The residue is dissolved in ether, filtered, washed with ether and dried in vacuo in the presence of potassium hydroxide. The output of 1.87 g (80%) of tripeptide; RJ 0.35-0.45. B. D-Alanyl-glycyl-L-phenylalanyl-L-isoleucine. 1.68 g (5 mmol) of H-Gly-Phe-Jle-OH (Example 4B) are suspended in 5 ml of pyridine, then 0.7 ml (5 lm) of triethylamine and 2.02 g (5 mmol) of ZD- are added. A1a-OCPR, stirred until the added substances were completely dissolved and left overnight. The reaction mixture was worked up as described in Example 4A. The resulting residue after evaporation (R 0.500, 55) is dissolved in 50 ml of 80% acetic acid and hydrogenated in the presence of a palladium catalyst. The catalyst is filtered off and washed with acetic acid. Acetic acid solutions are combined, evaporated, treated with ether, filtered, transferred with ether and dried in vacuo in the presence of potassium hydroxide. The output of 1.7 g (84%) of the tetrapeptide, Rr 0.10-0.15. B. 1-Tyrosyl-0-alanyl-glycyl-1-phenylalanyl-L-isoleucine.
    To a suspension of 1.22 g (3 mmol) H-0-A) a-Gly-Phe-J1e-OH (Example 4B) in pyridine, 0.42 ml (3 mmol) of triethylamine and 1.48 g (3 mmol A) Z-Tyr-OTCP, stirred until complete dissolution of the added substances and left overnight. The reaction mixture is treated analogously to example 4A. The residue obtained by evaporation (R 0.55-0.60) is dissolved in 50 ml of 80% acetic acid and hydrogenated with E in the presence of a palladium catalyst. The catalyst is filtered off and washed with acetic acid. Acetic acid solutions are combined, evaporated, dissolved in ether, filtered, washed with ether, and dried under vacuum in the presence of potassium hydroxide.
    The yield of 1.4 g (80%) specified in the title pentapeptide, 08-0,12. Amino Acid Analysis: Gly. 1.0; Ala 1.0; Nle 1.02, Tug 0.95, Phe 1 (for comparison).
    Example 5. Obtaining L-tyrosyl-0-alanyl-glycyl-1-phenylalanyl-L-Proline.
    A. Glycyl-L-phenylalanil-L-Proline,
    To suspensions of 5.25 g (20 mmOl) of H-Phe-Pro-OH in 20 ml of pyridine were added 2.8 ml (20 mmol) of triethylamine and 7.77 g (20 mmol) of Z-G1y-OTSR, stirred until complete additions added and allowed to stand overnight. The reaction mixture is treated analogously to example 4A. The product obtained by evaporation as a precipitate; R J 0.5-0.6) is dissolved
    in 100 ml
    to a
    methanol, hydrogenated in the presence of a palladium catalyst. After completion of the reaction, the catalyst is filtered off, washed with methanol, then the methanol solutions are combined and evaporated. The residue is crystallized from ether, filtered, washed with ether. rum, and dried.
    The output of 5.43 g (85%) of the specified tripeptide; Rj 0.31-0.38.
    B. D-Alanyl-GLYCYL-L-Phenylalanil-L-Proline ..
    3.2 g (10 mmol) of H-G1y-Phe-Pro-O (Example 5A) are suspended in 10 ml of pyridine, then 1.4 ml (10 mmol) of triethylamine and 4.03 g (10 mmol) of ZD- are added. Ala-OTCP was mixed until all the added substances were completely dissolved and left overnight. The reaction mixture was worked up as in Example 4A. The residue obtained by evaporation (Rj 0.42-0.53) is dissolved in 80 ml of methanol and hydrogenated in the presence of a palladium catalyst. At the end of the reaction, the catalyst is filtered off, rotted with methanol, then the methanol solutions are combined and evaporated. The residue is dissolved in ether, filtered, washed with ether and dried.
    The yield of 3.2 g (82%) specified in the name of the tetrapeptide; R 0,07-0,11
    B. Benzyloxycarbonyl-1-tyrosyl-D-alanyl-glicyl-L-phenylalanyl-L-prprlin.
    3.12 g (8 mmol)
    HD-Ala-Gly-Phe-OH (Example 5B) is suspended in 15 ml of pyridine, 1.12 MP (8 mmol) of triethylamine and 3.95 g (8 mmol) of Z-Tyr-OTCP are added and stirred until complete dissolution. substances left overnight. The reaction mixture is treated analogously to example 4A. The product obtained as a residue on evaporation is dissolved in ether, filtered, washed with ether and dried.
    Yield 4.4 g (80%) indicated in (Name of protected pentapeptide, R 0,3-0,4.
    G. 1-Tyrosyl-D-alanyl-GLYCIL-L-phenylalanyl-L-Proline.
    A solution of g (3 mol) of Z-Tyr-D-Ala-Cly-Phe-OH (Example 5B) in a mixture of 40 ml of methanol and 10 ml of dimethyl formamide is hydrogenated in the presence of a palladium catalyst. At the end of the reaction, the catalyst is filtered off, washed with a 1: 1 mixture of methanol and dimethylformamide, the solutions that are drained together are evaporated, the residue is dissolved in ether, filtered, washed with ether, dried, redissolved in 4 ml of ethanol and precipitated with ethyl acetate.
    The output of 1.16 g (70%) specified in the title Pentapeptide; R 0,3-0,4,
    Ag / acid test: Pro 1.02 Gly 1.0; Ala 0.98; Tug 1.0; Phe 1 (for comparison). About P b. Getting L-tyrosyl-D-alanyl-GLYCIL-L-phenylalanyl-L-proline-ethylamide.
    O, 7 g (1 mmol)
    Z-Tyr-D-A1a-G1y-Phe-Pro-OH (Example 5B) was dissolved in 2 ml of dimethylformamide, then 0.1 g (1.24 / IMoley) of ethylaminohydrochloride, 0.17 ml (1.24 mmol) of triethylamine and 0.21 g (1 mglol) of dicyclohexylcarbodiimide. The reaction mixture is left for a day, filtered, and diluted with 30 ml of ethyl acetate. The solution is washed with 0.5 n. hanoic acid, water, 5% sodium hydrogen carbonate solution and water are then dried and evaporated. After evaporation, the residue (R | 0.80-0.85) is dissolved in 30 ml of methanol and hydrogenated in the presence of a palladium catalyst. At the end of the reaction, the catalyst is filtered off, the solution is evaporated, the residue is triturated with ether, filtered, washed with ether and dried.
    The output of 0.43 g (0.75%) specified in the title Pentapeptide; R 0,34-0,44;
    And p and me R 7. Getting L-tyrosyl-0-methionyl-Glycyl-L-phenylalanyl-L-praline-hydrochloride.
    0.96 g (3 mmol) of HG) y-Phe-Pro-OH (Example 3) are suspended in 5 ml of pyridine, then 0.42 ml (2 mmol) of triethylamine and 1.27 ml (3 mmol) of Boc are added. -D-Met-OTCP, stirred until all the added substances had dissolved, and left overnight. The reaction mixture is treated analogously to example 4A. Then 10 ml 2. and. hydrochloric acid in ethyl acetate is poured onto the substance obtained by evaporation (R 0.30-0.35 and the mixture is stirred. After 30 min, the reaction mixture is diluted with n-heptane / filtered, washed with n-heptane and dried in vacuum in the presence of Potassium hydroxide. The product thus obtained (to | 0.16-0.24) is suspended in 5 ml of pyridine, then 0.84 ml (b mmol) of triethylamine and 1.32 g (2.5 mmol) of Boc-Tug are added. -ORST, stirred until all the added substances were completely dissolved, and left to stand overnight. The reaction mixture was worked up as in Example 4L. The precipitate is dissolved in 10 ml of 2N hydrochloric acid, ethyl acetate, filtered, washed with ethyl acetate and dried, yield 1.14 g (70%) of pentapeptide hydrochloride; Rj O, 35-0.45, Amino acid analysis: Pro 0.98 G Met 0.95; Ture 1.0; Phe 1 (for comparison). Example 8. Preparation of L-tyrosyl-0-norlecyl-glycyl-1-phenylalanyl-1-proline hydrochloride. Using 0.96 g (3 mmol A) H-G1y-Phe-Pro-OH (Example 5A) as the starting material, follow the procedure described in Example 7, with the difference that instead of 1.27 g of Boc-Met-OTCP, 1.06 g (3 mmo l) BOC-D-N1e-ONP. The output of 1.18 g (75%) of pentapeptide hydrochloride; R 0,35-0,45, Aminoki lot analysis: Pro 1.0; Gly 1.0 Nle 1, 05; 0.98; Phe 1 (for comparison). Example 9 Preparation of L-thyrozyl-0-methionyl-glycyl-1-phenylalanyl-L-proline ethylamide, A. Gl15Cyl-1-phenylalanyl-1-proline-ethylamide oxalate, 3.7 g (13 mmol) Pro The -NH-Et was dissolved in 50 ml of methanol and hydrogenated in the presence of a palladium catalyst. At the end of the reaction (, 2-0.3), the catalyst is filtered off, washed with methanol, methanol solution. evaporated and the residue is dissolved in 10 ml of dimethylformamide. After adding 3.9 g (13 mmol) of Z-Phe-OH, 1.75 g (13 mmol) of 1-hydroxybenztriazol and 2.7 g (13 mmol) of dicyclohecri carbodiimide, the reaction the mixture is left overnight and then evaporated. The residue is dissolved in 50 ml of ethyl acetate and then washed with 5% sodium hydrogen carbonate solution, 0.5N water. the sulfuric acid and the new aqueous organic phase are dried over sodium sulfate. evaporated. The product obtained (R 0.63-0.68) is dissolved in 50 ml of methanol and hydrogenated in the presence of a palladium catalyst. The catalyst is filtered off and the methanol solution is evaporated. The residue (R 0.1-0.2) is dissolved in 10 ml of pyridine, then 2.0.9 g (10 mmol) of Z-Gly-OTCP is added. The reaction mixture is left overnight, then evaporated. The residue after evaporation is dissolved in 50 ml of ethyl acetate, washed with 0.5 N sulfuric acid and the organic phase is dried over sodium sulfate and evaporated. The residue is dissolved in 50 ml of methanol and hydrogenated in the presence of a palladium catalyst. At the end of the reaction, the catalyst is filtered off and the solution is evaporated. The residue after evaporation is dissolved in a mixture of 2 ml of ethanol and 2 ml of ethyl acetate, then 0.9 g (10 mmol) of oxalic acid is added and the mixture is diluted with 50 ml of ethyl acetate. The precipitated product is filtered, washed with ethyl acetate and dried. Yield 2.7 g (62%) of tripeptidethylamidoxalate; m.p. 98-100 ° C; | 0.4-0.5, B. L-Tyrosyl-D-methionyl-glycyl-L-phenylalanyl-L-proline-ethylamide, 0.9 g (2 mmol) of the tripeptide ethylamidoxalate (Example 9A) is dissolved in 3 ml of pyridine , then 0.86 g (2 mmol) of Boc-0-Met-OTCP and 0.56 g (4 mmol) of triethylamine are added. The reaction mixture is left overnight, evaporated, the residue is dissolved in 30 ml of ethyl acetate, washed with 0.5 N, sulfuric acid, dried over sodium sulfate and evaporated. The residue (R. | 0,800, 85) is left with 10 ml of 3 N, sulfuric acid in ethyl acetate, after 30 minutes it is diluted with 30 ml of n-heptane, the resulting precipitate is filtered, washed with H-heptane and dried in vacuo in the presence of potassium hydroxide. The resulting product was dissolved in pyridine (5 ml) and 1.06 g (2 mmol) of Boc-Tug-OTPD and 0.56 ml (4 mmol) of triethylamine were added. The reaction mixture is left overnight, then evaporated, dissolved in 50 ml of ethyl acetate, washed with 0.5 N, sulfuric acid, dried over sodium sulfate and evaporated. The residue (R 0.85-0.90) was dissolved in 3 ml of trifluoroacetic acid and allowed to stand for 30 minutes. The solution is evaporated and the residue is triturated with a mixture of ethyl acetate and benzene (1: 1). The resulting product is dissolved in a mixture of 5 ml of 10% sodium carbonate solution and 50 ml of ethyl acetate. The aqueous phase is shaken with ethyl acetate (3 x 10 ml), combining -nen ethyl acetate phases are dried over sodium sulfate and evaporated. The residue after evaporation is triturated with a mixture of n-heptane and ethyl acetate (1: 1), the precipitate is filtered, washed with the same mixture, then with n-heptane and dried.
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining pentapeptides of the formula I with acetone, then the precipitated crystals are filtered off, washed with acetone and dried). The amidation reaction mixture was left overnight, filtered, evaporated, the residue after evaporation was dissolved in methylene chloride, washed with 5% sodium hydrogen carbonate solution, dried over sodium sulfate and evaporated. The evaporation residue (R ^ 0.53-0.58) is dissolved in 10 ml of trifluoroacetic acid, left for 30 min at room temperature, then evaporated and the residue (Rp 0.50-0.60) is dried in vacuum in the presence of hydroxide potassium. The resulting product is dissolved 55 in 30-40 ml of a mixture of chloroform and n-butanol (3: 1) and 5-7 mm of water. The aqueous phase is neutralized with solid acidic sodium carbonate, extracted with the specified mixture of chloroform and n-buta-
    Tyr-A-G1y-Phe-B-X-Y, Where A - D-Ala, D-NLeu, D-Me t,IN - N-Leu, Isoea, Pro,X - 0, NH, At - H, Me, Et or them ethers or their amides, or them salts, oh, t run wild with i by that norleucine, josoleucine or
    proline or their ester or amide derivatives are condensed with the following amino acids and / or peptide fragments having N-terminal cleavable protecting groups, followed by · deprotection and isolation of the desired product in the form of an ester, amide, salt or acid.
    类似技术:
    公开号 | 公开日 | 专利标题
    Brady et al.1979|Practical synthesis of cyclic peptides, with an example of dependence of cyclization yield upon linear sequence
    SU772481A3|1980-10-15|Method of preparing pentapeptides or their esters of their salts
    Isowa et al.1977|The enzymatic synthesis of protected valine-5 angiotensin II amide-1
    DK149630B|1986-08-18|METHOD OF ANALOGUE FOR THE PREPARATION OF TRIPEPTIDAMIDES OR ESTERS OR PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALTS.
    DK151968B|1988-01-18|METHOD FOR PREPARING PENTAPEPTID H-ARG-X-ASP-Y-TIRE-R BY SOLUTION SYNTHESIS
    Tanaka et al.1980|Studies on 2-aziridinecarboxylic acid. IV. total synthesis of actinomycin D | via ring-opening reaction of aziridine
    EP0001684B1|1981-09-02|Tetrapeptides, methods for their preparation and their use in analgesic compositions
    Ye et al.1998|Enzymatic syntheses of N-protected Leu-enkephalin and some oligopeptides in organic solvents
    US3917578A|1975-11-04|Process for producing somatostatin and intermediates
    Izumiya et al.1964|Studies of Peptide Antibiotics. I. Dipeptide Anhydrides as Models of Cyclic Peptide Antibiotics
    SU993816A3|1983-01-30|Process for preparing octapeptides
    US3299035A|1967-01-17|L-aspartyl-l-alanyl-l-phenylalanyl-l-isoleucyl-glycyl-l-leucyl-l-methioninamide and its acid addition salts
    Sato et al.1977|Studies of Peptide Antibiotics. XXXV. Synthesis of Gramicidin S by a Fragment Solid-Phase Method
    Pettit et al.1986|Structural biochemistry. 25. Antineoplastic agents. 110. Synthesis of the dolastatin 3 isomer cyclo [L-Pro-L-Leu-L-Val-|-| Thz-| Thz]
    US4204991A|1980-05-27|Sarcosine1 dehydroalanine8 angiotensin II derivatives
    Shimonishi1964|Studies of the Synthesis of Peptides Containing C-Terminal Glutamine. II The Synthesis and Use of α-p-Nitrobenzyl γ-Methyl L-Glutamate
    US3272790A|1966-09-13|Polypeptides
    Sugano et al.1974|Studies of peptide antibiotics. XXX. Syntheses of gramicidin S analogs containing N-methylleucine in place of leucine
    US3280098A|1966-10-18|Process of producing peptides and products obtained thereby
    Ariyoshi et al.1967|Synthetic studies of bacitracin. II. Synthesis of a cyclic dodecapeptide, an analogue of bacitracin A
    US3948971A|1976-04-06|N-protected-α-amino acid compounds
    US3417072A|1968-12-17|Intermediates in the synthesis of secretin
    US3247178A|1966-04-19|Synthesis of peptides containing alpha, omega-diamino acids protected by phthalyl and t-butyloxycarbonyl groups
    Waki et al.1968|Ribonuclease T1 peptides. II. Synthesis of a protected pentapeptide corresponding to sequence 12–16
    Kondo et al.1966|Studies of Peptide Antibiotics. VI. Syntheses of Cyclic Penta and Decapeptides with a Glycyl-L-ornithyl-L-leucyl-D-phenylalanylglycyl Sequence
    同族专利:
    公开号 | 公开日
    DK409277A|1978-03-17|
    SE440658B|1985-08-12|
    DE2740699C2|1987-10-01|
    ATA632377A|1980-05-15|
    DK149077C|1986-06-16|
    DE2740699A1|1978-03-23|
    BE858453A|1978-03-07|
    US4465625A|1984-08-14|
    FR2364890B1|1984-03-23|
    GB1584968A|1981-02-18|
    DD132127A5|1978-08-30|
    HU178001B|1982-02-28|
    AT360184B|1980-12-29|
    JPS5340735A|1978-04-13|
    NL7709636A|1978-03-20|
    SE7709913L|1978-03-17|
    PL114062B1|1981-01-31|
    CS199708B2|1980-07-31|
    DK149077B|1986-01-13|
    CH636599A5|1983-06-15|
    PL200857A1|1979-06-04|
    JPS602319B2|1985-01-21|
    FR2364890A1|1978-04-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    HU184704B|1976-01-26|1984-10-29|Wellcome Found|Process for preparing biologically active encephaline analogues|
    GB1532181A|1976-02-02|1978-11-15|Beckman Instruments Inc|Pentapetides and a method of preparing them|
    NZ183712A|1976-04-08|1979-10-25|Ici Ltd|Polypeptide analogues of enkephalins, and pharmaceutical compositions|
    DE2732451A1|1976-07-27|1978-02-02|Reckitt & Colmann Prod Ltd|Peptide morphine agonists - for use as analgesics, sedatives, antitussives, etc.|
    US4259234A|1976-09-27|1981-03-31|Eli Lilly And Company|Analgesic compounds|
    IT1107551B|1977-07-22|1985-11-25|Wellcome Found|PENTAPEPTIDES USEFUL AS MEDICATIONS IN HUMAN AND VETERINARY MEDICINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM COEM ACTIVE INGREDIENT|FR2353040B1|1976-05-25|1979-10-12|Europ Propulsion|
    FR2359817B1|1976-07-27|1981-01-02|Reckitt & Colmann Prod Ltd|
    US4259234A|1976-09-27|1981-03-31|Eli Lilly And Company|Analgesic compounds|
    GB2000784B|1977-07-05|1982-01-20|American Home Prod|Analgesic polypetide|
    IT1107551B|1977-07-22|1985-11-25|Wellcome Found|PENTAPEPTIDES USEFUL AS MEDICATIONS IN HUMAN AND VETERINARY MEDICINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM COEM ACTIVE INGREDIENT|
    GB1604850A|1977-11-24|1981-12-16|Wellcome Found|Biologically active peptides|
    FR2424253B1|1978-04-27|1981-01-02|Janssen Lebrun|
    NL8005121A|1979-09-20|1981-03-24|Erba Farmitalia|ORGANICALLY ACTIVE PEPTIDES.|
    HU181013B|1980-01-25|1983-05-30|Gyogyszerkutato Intezet|Process for preparing new enkephalin analogues|
    WO1982000640A1|1980-08-18|1982-03-04|Akita T|Tripeptide alkylamide derivatives|
    DE3333752A1|1983-09-19|1985-04-11|Victor Dipl.- Chem. 8000 München Brantl|PHARMACOLOGICALLY ACTIVE PEPTIDES|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU76GO1350A|HU178001B|1976-09-16|1976-09-16|Process for preparing new pentapeptides with morphine-like activity and derivatives thereof|
    [返回顶部]